StockSelector.com
  Research, Select, & Monitor Sunday, December 17, 2017 3:14:13 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Revance Therapeutics, Inc.$32.05($.10)(.31%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Revance Therapeutics, Inc. has an overall rank of 7144 out of 7423 stocks based on 5 positive rankings and 9 negative rankings.

Positive Rankings
10 Day Gain
Revance Therapeutics rank is 287
Debt-to-Equity
Revance Therapeutics rank is 323
90 Day Gain
Revance Therapeutics rank is 436
Target Prices
The average analysts' target price is $37.00 for Revance Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Revance Therapeutics is ranked 572.
Low vPut/Call
Revance Therapeutics has a low Put/Call ratio of 0.34 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Revance Therapeutics is ranked 828.
Negative Rankings
Price-to-Sales
Revance Therapeutics rank is 10
Negative Net Margin
Revance Therapeutics rank is 21
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Revance Therapeutics is ranked 109.
Down EPS Surprise
Revance Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Negative Revenue Growth
Revance Therapeutics rank is 433
Negative ROE
Revance Therapeutics rank is 621
Negative ROA
Revance Therapeutics rank is 647
Price-to-Book
Revance Therapeutics rank is 965
High Put/Call
Revance Therapeutics has a high Put/Call ratio of 0.88 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Revance Therapeutics is ranked 1219.







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.